Inozyme Pharma Stock Buy Hold or Sell Recommendation
| INZY Stock | USD 1.37 0.02 1.48% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Inozyme Pharma is 'Strong Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Inozyme Pharma given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Inozyme Pharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Inozyme Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide. In addition, we conduct extensive research on individual companies such as Inozyme and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Inozyme Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Inozyme |
Execute Inozyme Pharma Buy or Sell Advice
The Inozyme recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Inozyme Pharma. Macroaxis does not own or have any residual interests in Inozyme Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Inozyme Pharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Inozyme Pharma Trading Alerts and Improvement Suggestions
| Inozyme Pharma generated a negative expected return over the last 90 days | |
| Inozyme Pharma has high historical volatility and very poor performance | |
| Inozyme Pharma may become a speculative penny stock | |
| Inozyme Pharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (71.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inozyme Pharma currently holds about 151.48 M in cash with (70.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Inozyme Pharma has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Inozyme Pharma, Inc. Receives Average Rating of Buy from Brokerages - MarketBeat |
Inozyme Pharma Returns Distribution Density
The distribution of Inozyme Pharma's historical returns is an attempt to chart the uncertainty of Inozyme Pharma's future price movements. The chart of the probability distribution of Inozyme Pharma daily returns describes the distribution of returns around its average expected value. We use Inozyme Pharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Inozyme Pharma returns is essential to provide solid investment advice for Inozyme Pharma.
| Mean Return | -1.42 | Value At Risk | -8.75 | Potential Upside | 7.72 | Standard Deviation | 6.14 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Inozyme Pharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Inozyme Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Inozyme Pharma, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Inozyme Pharma back and forth among themselves.
| Shares | Millennium Management Llc | 2024-09-30 | 1.7 M | Samsara Biocapital, Llc | 2024-09-30 | 1.6 M | Saturn V Capital Management Llc | 2024-09-30 | 1.4 M | Sphera Funds Management Ltd. | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Blue Owl Capital Holdings Lp | 2024-09-30 | 1.1 M | State Street Corp | 2024-09-30 | 1.1 M | Woodline Partners Lp | 2024-09-30 | 1 M | Goldman Sachs Group Inc | 2024-09-30 | 447.3 K | Adage Capital Partners Gp Llc | 2024-09-30 | 5.7 M | Pivotal Bioventure Partners Investment Advisor Llc | 2024-09-30 | 4.5 M |
Inozyme Pharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (117.2M) | 43.2M | (5.0M) | (44.0M) | (39.6M) | (37.6M) | |
| Change In Cash | (3.3M) | (4.7M) | 9.6M | 1.6M | 1.5M | 1.4M | |
| Free Cash Flow | (36.5M) | (48.6M) | (58.2M) | (71.0M) | (63.9M) | (67.1M) | |
| Depreciation | 217K | 674K | 744K | 833K | 958.0K | 1.0M | |
| Other Non Cash Items | 18.0M | 378K | (1.1M) | (4.3M) | (3.9M) | (3.7M) | |
| Capital Expenditures | 568K | 397K | 410K | 298K | 342.7K | 379.7K | |
| Net Income | (56.4M) | (56.6M) | (67.1M) | (71.2M) | (64.1M) | (67.3M) | |
| End Period Cash Flow | 28.4M | 23.7M | 33.3M | 34.9M | 31.4M | 25.1M | |
| Change To Netincome | 230K | 20.3M | 7.7M | 7.7M | 8.8M | 7.0M |
Inozyme Pharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Inozyme Pharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Inozyme Pharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Inozyme stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.43 | |
β | Beta against Dow Jones | 1.38 | |
σ | Overall volatility | 6.20 | |
Ir | Information ratio | -0.23 |
Inozyme Pharma Volatility Alert
Inozyme Pharma is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inozyme Pharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inozyme Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Inozyme Pharma Fundamentals Vs Peers
Comparing Inozyme Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Inozyme Pharma's direct or indirect competition across all of the common fundamentals between Inozyme Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Inozyme Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Inozyme Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Inozyme Pharma to competition |
| Fundamentals | Inozyme Pharma | Peer Average |
| Return On Equity | -0.79 | -0.31 |
| Return On Asset | -0.36 | -0.14 |
| Current Valuation | 3.19 M | 16.62 B |
| Shares Outstanding | 64.24 M | 571.82 M |
| Shares Owned By Insiders | 1.30 % | 10.09 % |
| Shares Owned By Institutions | 92.50 % | 39.21 % |
| Number Of Shares Shorted | 3.66 M | 4.71 M |
| Price To Book | 1.06 X | 9.51 X |
| EBITDA | (74.81 M) | 3.9 B |
| Net Income | (71.17 M) | 570.98 M |
| Cash And Equivalents | 151.48 M | 2.7 B |
| Cash Per Share | 3.77 X | 5.01 X |
| Total Debt | 46.59 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 14.54 X | 2.16 X |
| Book Value Per Share | 1.29 X | 1.93 K |
| Cash Flow From Operations | (70.67 M) | 971.22 M |
| Short Ratio | 3.66 X | 4.00 X |
| Earnings Per Share | (1.55) X | 3.12 X |
| Price To Earnings To Growth | (0.06) X | 4.89 X |
| Target Price | 18.0 | |
| Number Of Employees | 59 | 18.84 K |
| Beta | 1.29 | -0.15 |
| Market Capitalization | 88.01 M | 19.03 B |
| Total Asset | 200.85 M | 29.47 B |
| Retained Earnings | (285.93 M) | 9.33 B |
| Working Capital | 181.56 M | 1.48 B |
| Net Asset | 200.85 M |
Note: Disposition of 25000 shares by Douglas Treco of Inozyme Pharma subject to Rule 16b-3 [view details]
Inozyme Pharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Inozyme . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Inozyme Pharma Buy or Sell Advice
When is the right time to buy or sell Inozyme Pharma? Buying financial instruments such as Inozyme Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Inozyme Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investment Grade ETFs Thematic Idea Now
Investment Grade ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 268 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.